Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q83411271 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241020233049.0 | ||
| 008 | 241020nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q83411271 | ||
| 024 | ‡a 0000-0001-7414-5278 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q83411271 | ||
| 100 | 0 | ‡a Juan María Borreguero León ‡c researcher ‡9 en | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a Juan María Borreguero León ‡c wetenschapper ‡9 nl | |
| 400 | 0 | ‡a Juan María Borreguero León ‡c investigador ‡9 es | |
| 670 | ‡a Author's Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction. | ||
| 670 | ‡a Author's Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. | ||
| 670 | ‡a Author's Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury. | ||
| 670 | ‡a Author's Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. | ||
| 670 | ‡a Author's Hidden cocaine consumption in neurological emergencies | ||
| 670 | ‡a Author's High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients | ||
| 670 | ‡a Author's High Serum sCD40L Levels During the First Week of Malignant Middle Cerebral Artery Infarction and Mortality | ||
| 670 | ‡a Author's Higher serum caspase-cleaved cytokeratin-18 levels during the first week of sepsis diagnosis in non-survivor patients. | ||
| 670 | ‡a Author's Incidence and impact of undisclosed cocaine use in emergency department chest pain and trauma patients | ||
| 670 | ‡a Author's Influence of TIMP-1/MMP-9 ratio on the severity and mortality in sepsis | ||
| 670 | ‡a Author's Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. | ||
| 670 | ‡a Author's Nonsurviving Patients with Severe Traumatic Brain Injury Have Maintained High Serum sCD40L Levels | ||
| 670 | ‡a Author's Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients | ||
| 670 | ‡a Author's Prognostic value of malondialdehyde serum levels in severe sepsis: a multicenter study. | ||
| 670 | ‡a Author's Red blood cell distribution width during the first week is associated with severity and mortality in septic patients | ||
| 670 | ‡a Author's Serum caspase-3 levels and mortality are associated in patients with severe traumatic brain injury | ||
| 670 | ‡a Author's Serum caspase 3 levels are associated with early mortality in severe septic patients. | ||
| 670 | ‡a Author's Serum levels of caspase-cleaved cytokeratin-18 and mortality are associated in severe septic patients: pilot study | ||
| 670 | ‡a Author's Serum levels of caspase-cleaved cytokeratin-18 in patients with severe traumatic brain injury are associated with mortality: a pilot study | ||
| 670 | ‡a Author's Serum melatonin levels are associated with mortality in severe septic patients | ||
| 670 | ‡a Author's Serum soluble CD40 Ligand levels are associated with severity and mortality of brain trauma injury patients. | ||
| 670 | ‡a Author's Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction | ||
| 670 | ‡a Author's Severe septic patients with mitochondrial DNA haplogroup JT show higher survival rates: a prospective, multicenter, observational study. | ||
| 670 | ‡a Author's Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients | ||
| 670 | ‡a Author's The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. | ||
| 670 | ‡a Author's The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis | ||
| 670 | ‡a Author's Undisclosed cocaine use and chest pain in emergency departments of Spain. | ||
| 670 | ‡a Author's Vascular risk factors and retinal occlusive disease | ||
| 909 | ‡a (orcid) 0000000174145278 ‡9 1 | ||
| 919 | ‡a associationbetweenserumsolublecd154levelsandmortalityinpatientswithmalignantmiddlecerebralarteryinfarction ‡A Association between Serum Soluble CD154 Levels and Mortality in Patients with Malignant Middle Cerebral Artery Infarction. ‡9 1 | ||
| 919 | ‡a associationbetweenserumsolublecd40ligandlevelsandmortalityinpatientswithseveresepsis ‡A Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. ‡9 1 | ||
| 919 | ‡a associationbetweenserumtissueinhibitorofmatrixmetalloproteinase1levelsandmortalityinpatientswithseverebraintraumainjury ‡A Association between serum tissue inhibitor of matrix metalloproteinase-1 levels and mortality in patients with severe brain trauma injury. ‡9 1 | ||
| 919 | ‡a associationofsepsisrelatedmortalitywithearlyincreaseoftimp1mmp9ratio ‡A Association of sepsis-related mortality with early increase of TIMP-1/MMP-9 ratio. ‡9 1 | ||
| 919 | ‡a hiddencocaineconsumptioninneurologicalemergencies ‡A Hidden cocaine consumption in neurological emergencies ‡9 1 | ||
| 919 | ‡a highserumlevelsoftissueinhibitorofmatrixmetalloproteinase1duringthe1weekofamalignantmiddlecerebralarteryinfarctioninnonsurvivingpatients ‡A High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients ‡9 1 | ||
| 919 | ‡a highserumscd40llevelsduringthe1weekofmalignantmiddlecerebralarteryinfarctionandmortality ‡A High Serum sCD40L Levels During the First Week of Malignant Middle Cerebral Artery Infarction and Mortality ‡9 1 | ||
| 919 | ‡a higherserumcaspasecleavedcytokeratin18levelsduringthe1weekofsepsisdiagnosisinnonsurvivorpatients ‡A Higher serum caspase-cleaved cytokeratin-18 levels during the first week of sepsis diagnosis in non-survivor patients. ‡9 1 | ||
| 919 | ‡a incidenceandimpactofundisclosedcocaineuseinemergencydepartmentchestpainandtraumapatients ‡A Incidence and impact of undisclosed cocaine use in emergency department chest pain and trauma patients ‡9 1 | ||
| 919 | ‡a influenceoftimp1mmp9ratioontheseverityandmortalityinsepsis ‡A Influence of TIMP-1/MMP-9 ratio on the severity and mortality in sepsis ‡9 1 | ||
| 919 | ‡a matrixmetalloproteinase910andtissueinhibitorofmatrixmetalloproteinases1bloodlevelsasbiomarkersofseverityandmortalityinsepsis ‡A Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis. ‡9 1 | ||
| 919 | ‡a nonsurvivingpatientswithseveretraumaticbraininjuryhavemaintainedhighserumscd40llevels ‡A Nonsurviving Patients with Severe Traumatic Brain Injury Have Maintained High Serum sCD40L Levels ‡9 1 | ||
| 919 | ‡a persistentlyhighcirculatingtissueinhibitorofmatrixmetalloproteinase1levelsinnonsurvivorbraintraumainjurypatients ‡A Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients ‡9 1 | ||
| 919 | ‡a prognosticvalueofmalondialdehydeserumlevelsinseveresepsisamulticenterstudy ‡A Prognostic value of malondialdehyde serum levels in severe sepsis: a multicenter study. ‡9 1 | ||
| 919 | ‡a redbloodcelldistributionwidthduringthe1weekisassociatedwithseverityandmortalityinsepticpatients ‡A Red blood cell distribution width during the first week is associated with severity and mortality in septic patients ‡9 1 | ||
| 919 | ‡a serumcaspase3levelsandmortalityareassociatedinpatientswithseveretraumaticbraininjury ‡A Serum caspase-3 levels and mortality are associated in patients with severe traumatic brain injury ‡9 1 | ||
| 919 | ‡a serumcaspase3levelsareassociatedwithearlymortalityinseveresepticpatients ‡A Serum caspase 3 levels are associated with early mortality in severe septic patients. ‡9 1 | ||
| 919 | ‡a serumlevelsofcaspasecleavedcytokeratin18andmortalityareassociatedinseveresepticpatientspilotstudy ‡A Serum levels of caspase-cleaved cytokeratin-18 and mortality are associated in severe septic patients: pilot study ‡9 1 | ||
| 919 | ‡a serumlevelsofcaspasecleavedcytokeratin18inpatientswithseveretraumaticbraininjuryareassociatedwithmortalityapilotstudy ‡A Serum levels of caspase-cleaved cytokeratin-18 in patients with severe traumatic brain injury are associated with mortality: a pilot study ‡9 1 | ||
| 919 | ‡a serummelatoninlevelsareassociatedwithmortalityinseveresepticpatients ‡A Serum melatonin levels are associated with mortality in severe septic patients ‡9 1 | ||
| 919 | ‡a serumsolublecd40ligandlevelsareassociatedwithseverityandmortalityofbraintraumainjurypatients ‡A Serum soluble CD40 Ligand levels are associated with severity and mortality of brain trauma injury patients. ‡9 1 | ||
| 919 | ‡a serumtissueinhibitorofmatrixmetalloproteinase1levelsareassociatedwithmortalityinpatientswithmalignantmiddlecerebralarteryinfarction ‡A Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction ‡9 1 | ||
| 919 | ‡a severesepticpatientswithmitochondrialdnahaplogroupjtshowhighersurvivalratesaprospectivemulticenterobservationalstudy ‡A Severe septic patients with mitochondrial DNA haplogroup JT show higher survival rates: a prospective, multicenter, observational study. ‡9 1 | ||
| 919 | ‡a sustainedhighplasmaplasminogenactivatorinhibitor1levelsareassociatedwithseverityandmortalityinsepticpatients ‡A Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients ‡9 1 | ||
| 919 | ‡a 372t100geneticpolymorphismoftimp1isassociatedwithserumlevelsoftimp1andsurvivalinpatientswithseveresepsis ‡A The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis. ‡9 1 | ||
| 919 | ‡a 4g4ggenotypeofpai1polymorphismisassociatedwithhigherplasmapai1concentrationsandmortalityinpatientswithseveresepsis ‡A The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis ‡9 1 | ||
| 919 | ‡a undisclosedcocaineuseandchestpaininemergencydepartmentsofspain ‡A Undisclosed cocaine use and chest pain in emergency departments of Spain. ‡9 1 | ||
| 919 | ‡a vascularriskfactorsandretinalocclusivedisease ‡A Vascular risk factors and retinal occlusive disease ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 BNE|XX5081890 | ||
| 996 | ‡2 BNE|XX5081891 | ||
| 996 | ‡2 BNE|XX5081892 | ||
| 996 | ‡2 BNE|XX4981574 | ||
| 996 | ‡2 RERO|A000073170 | ||
| 996 | ‡2 BNE|XX1080393 | ||
| 996 | ‡2 CAOONL|ncf11386940 | ||
| 996 | ‡2 SUDOC|102551804 | ||
| 996 | ‡2 ISNI|000000039214445X | ||
| 996 | ‡2 BNF|13800142 | ||
| 996 | ‡2 LC|no 94023863 | ||
| 996 | ‡2 BNE|XX6089599 | ||
| 996 | ‡2 BNC|981058510064306706 | ||
| 996 | ‡2 PTBNP|148377 | ||
| 996 | ‡2 SUDOC|269366679 | ||
| 996 | ‡2 BNE|XX5532524 | ||
| 996 | ‡2 SUDOC|066898595 | ||
| 996 | ‡2 BNE|XX5877706 | ||
| 996 | ‡2 DNB|1198282045 | ||
| 996 | ‡2 LC|no 96059032 | ||
| 996 | ‡2 BNCHL|10000000000000000150164 | ||
| 996 | ‡2 ISNI|0000000051448631 | ||
| 996 | ‡2 ISNI|0000000079900992 | ||
| 996 | ‡2 LC|no 98087810 | ||
| 996 | ‡2 SUDOC|035020830 | ||
| 996 | ‡2 DNB|138229600 | ||
| 996 | ‡2 SUDOC|243007922 | ||
| 996 | ‡2 ISNI|0000000059818764 | ||
| 996 | ‡2 ISNI|0000000079885577 | ||
| 996 | ‡2 DNB|1057664375 | ||
| 996 | ‡2 SUDOC|176285229 | ||
| 996 | ‡2 DNB|13328137X | ||
| 996 | ‡2 SUDOC|231522460 | ||
| 996 | ‡2 BNE|XX6434881 | ||
| 996 | ‡2 PTBNP|89412 | ||
| 996 | ‡2 LC|no2022028888 | ||
| 996 | ‡2 BNC|981058618208206706 | ||
| 996 | ‡2 LC|ns2022001524 | ||
| 996 | ‡2 BNE|XX5557290 | ||
| 996 | ‡2 BIBSYS|90272982 | ||
| 996 | ‡2 DNB|121297780 | ||
| 996 | ‡2 LC|no2005003949 | ||
| 996 | ‡2 ISNI|0000000504113587 | ||
| 996 | ‡2 LIH|LNB:DCZ_d_;=B_b_ | ||
| 996 | ‡2 BNF|12074409 | ||
| 996 | ‡2 DNB|131412450 | ||
| 996 | ‡2 DNB|1158178689 | ||
| 996 | ‡2 LC|no2009127039 | ||
| 996 | ‡2 ISNI|0000000439810772 | ||
| 996 | ‡2 NTA|141243252 | ||
| 996 | ‡2 LC|n 2014189542 | ||
| 996 | ‡2 LC|no2006096792 | ||
| 996 | ‡2 BNE|XX1172370 | ||
| 996 | ‡2 SUDOC|156216493 | ||
| 996 | ‡2 ISNI|0000000109504377 | ||
| 996 | ‡2 BNC|981058521199506706 | ||
| 996 | ‡2 BNF|16030420 | ||
| 996 | ‡2 ISNI|0000000430890219 | ||
| 996 | ‡2 MRBNR|vtls000298888 | ||
| 996 | ‡2 ISNI|0000000016557402 | ||
| 996 | ‡2 SUDOC|181267993 | ||
| 996 | ‡2 ISNI|0000000115795676 | ||
| 996 | ‡2 LC|no2003116005 | ||
| 996 | ‡2 ISNI|0000000048845548 | ||
| 996 | ‡2 DNB|1056193603 | ||
| 996 | ‡2 ISNI|0000000121308694 | ||
| 996 | ‡2 BNC|981060944760306706 | ||
| 996 | ‡2 LC|n 78003458 | ||
| 996 | ‡2 ISNI|0000000059373638 | ||
| 996 | ‡2 LC|ns2018001611 | ||
| 996 | ‡2 LC|n 2012049219 | ||
| 996 | ‡2 DNB|1061552454 | ||
| 996 | ‡2 ISNI|0000000052971635 | ||
| 996 | ‡2 BNE|XX5745825 | ||
| 996 | ‡2 ISNI|000000050128310X | ||
| 996 | ‡2 LC|n 50023981 | ||
| 996 | ‡2 LC|n 2019035003 | ||
| 996 | ‡2 LC|no2024052629 | ||
| 996 | ‡2 CAOONL|ncf11886230 | ||
| 996 | ‡2 DNB|1057667234 | ||
| 996 | ‡2 DNB|1082385832 | ||
| 996 | ‡2 BNF|13010417 | ||
| 996 | ‡2 BNCHL|10000000000000000810738 | ||
| 996 | ‡2 BNE|XX1378385 | ||
| 996 | ‡2 PLWABN|9810665910505606 | ||
| 996 | ‡2 DNB|1056497297 | ||
| 996 | ‡2 BNCHL|10000000000000000122344 | ||
| 996 | ‡2 LC|n 2008183609 | ||
| 996 | ‡2 DNB|1201392586 | ||
| 996 | ‡2 DNB|1037551540 | ||
| 996 | ‡2 ISNI|0000000117535886 | ||
| 996 | ‡2 ISNI|0000000059363843 | ||
| 996 | ‡2 CAOONL|ncf10727587 | ||
| 996 | ‡2 LC|no2018129424 | ||
| 996 | ‡2 DNB|119413671 | ||
| 996 | ‡2 ISNI|0000000365310643 | ||
| 996 | ‡2 SUDOC|151018545 | ||
| 996 | ‡2 LC|n 85158439 | ||
| 996 | ‡2 LC|nr2003040004 | ||
| 996 | ‡2 BNC|981060034160206706 | ||
| 996 | ‡2 PTBNP|1470755 | ||
| 996 | ‡2 BNE|XX1142792 | ||
| 996 | ‡2 LC|no2009064968 | ||
| 996 | ‡2 NUKAT|n 2020155472 | ||
| 996 | ‡2 LC|no2011059559 | ||
| 996 | ‡2 NII|DA1668748X | ||
| 996 | ‡2 J9U|987007380398905171 | ||
| 996 | ‡2 ISNI|0000000395423702 | ||
| 996 | ‡2 BNE|XX1105422 | ||
| 996 | ‡2 SUDOC|147350808 | ||
| 996 | ‡2 SUDOC|203384172 | ||
| 996 | ‡2 PLWABN|9810540974905606 | ||
| 996 | ‡2 SUDOC|121729346 | ||
| 996 | ‡2 ISNI|000000007754818X | ||
| 996 | ‡2 LC|n 2005044053 | ||
| 996 | ‡2 LC|n 2011060246 | ||
| 996 | ‡2 SUDOC|265786061 | ||
| 996 | ‡2 LC|nr 99025650 | ||
| 996 | ‡2 SUDOC|032237944 | ||
| 996 | ‡2 BNE|XX1010812 | ||
| 996 | ‡2 BNE|XX1611497 | ||
| 996 | ‡2 BNE|XX832208 | ||
| 996 | ‡2 DNB|1014898145 | ||
| 996 | ‡2 SUDOC|176923233 | ||
| 996 | ‡2 BIBSYS|1642068490051 | ||
| 996 | ‡2 LC|n 85136049 | ||
| 996 | ‡2 SUDOC|124438997 | ||
| 996 | ‡2 SUDOC|061725811 | ||
| 996 | ‡2 NTA|070182752 | ||
| 996 | ‡2 LIH|LNB:C_a__i_L;=B_p_ | ||
| 996 | ‡2 BNF|15067165 | ||
| 996 | ‡2 ISNI|0000000115776184 | ||
| 996 | ‡2 J9U|987007268604805171 | ||
| 996 | ‡2 BNE|XX1073655 | ||
| 996 | ‡2 BNE|XX1056866 | ||
| 996 | ‡2 BNCHL|10000000000000000123546 | ||
| 996 | ‡2 BNE|XX1140291 | ||
| 996 | ‡2 BNC|981058509354906706 | ||
| 996 | ‡2 W2Z|1642068490051 | ||
| 996 | ‡2 NTA|12460790X | ||
| 996 | ‡2 DNB|171087143 | ||
| 996 | ‡2 SUDOC|262571293 | ||
| 996 | ‡2 SUDOC|175803285 | ||
| 996 | ‡2 BNCHL|10000000000000000268928 | ||
| 996 | ‡2 NUKAT|n 2015195380 | ||
| 996 | ‡2 BNC|981058620333806706 | ||
| 996 | ‡2 ISNI|0000000040700651 | ||
| 996 | ‡2 SUDOC|271377135 | ||
| 996 | ‡2 LC|no2017133069 | ||
| 996 | ‡2 ISNI|0000000050627013 | ||
| 996 | ‡2 PTBNP|1669054 | ||
| 996 | ‡2 SUDOC|086246909 | ||
| 996 | ‡2 ISNI|0000000448808367 | ||
| 996 | ‡2 BNE|XX6472158 | ||
| 996 | ‡2 DNB|1070717266 | ||
| 996 | ‡2 ISNI|0000000440085758 | ||
| 996 | ‡2 ISNI|0000000026098756 | ||
| 996 | ‡2 BNE|XX871348 | ||
| 996 | ‡2 ISNI|0000000062213547 | ||
| 996 | ‡2 JPG|500099302 | ||
| 996 | ‡2 LC|n 87103893 | ||
| 996 | ‡2 J9U|987007491742005171 | ||
| 996 | ‡2 LC|no2010017658 | ||
| 996 | ‡2 ISNI|0000000028461344 | ||
| 996 | ‡2 SUDOC|030242584 | ||
| 996 | ‡2 PTBNP|1493744 | ||
| 996 | ‡2 BNF|18102163 | ||
| 996 | ‡2 LC|no2015037360 | ||
| 996 | ‡2 LC|n 96023538 | ||
| 996 | ‡2 ISNI|0000000367167158 | ||
| 996 | ‡2 ISNI|0000000451346300 | ||
| 996 | ‡2 BNF|15554875 | ||
| 996 | ‡2 DNB|1056797754 | ||
| 996 | ‡2 LC|no2021108160 | ||
| 996 | ‡2 ISNI|0000000452146706 | ||
| 996 | ‡2 RERO|A003883372 | ||
| 996 | ‡2 DNB|1060683105 | ||
| 996 | ‡2 SUDOC|276389883 | ||
| 996 | ‡2 SUDOC|074071327 | ||
| 996 | ‡2 NTA|320514897 | ||
| 996 | ‡2 ISNI|000000038542770X | ||
| 996 | ‡2 LC|no2020115987 | ||
| 996 | ‡2 BNF|14616971 | ||
| 996 | ‡2 ISNI|0000000002054310 | ||
| 996 | ‡2 SUDOC|026983427 | ||
| 996 | ‡2 ISNI|0000000428204160 | ||
| 996 | ‡2 J9U|987007428551205171 | ||
| 996 | ‡2 SUDOC|06939427X | ||
| 996 | ‡2 ISNI|0000000442736999 | ||
| 996 | ‡2 BNE|XX5536499 | ||
| 996 | ‡2 BIBSYS|10033743 | ||
| 996 | ‡2 ISNI|0000000061009819 | ||
| 996 | ‡2 DNB|1056528664 | ||
| 996 | ‡2 ISNI|0000000045422726 | ||
| 996 | ‡2 J9U|987007360416305171 | ||
| 996 | ‡2 ISNI|0000000071148628 | ||
| 996 | ‡2 DNB|1057757209 | ||
| 996 | ‡2 LC|no2007104052 | ||
| 996 | ‡2 LC|n 89129467 | ||
| 996 | ‡2 JPG|500015824 | ||
| 996 | ‡2 BNF|12232164 | ||
| 996 | ‡2 BNCHL|10000000000000000111078 | ||
| 996 | ‡2 LC|no2007127146 | ||
| 996 | ‡2 DNB|1192481674 | ||
| 996 | ‡2 BNE|XX6221148 | ||
| 996 | ‡2 ISNI|0000000474249036 | ||
| 996 | ‡2 ISNI|0000000032727344 | ||
| 996 | ‡2 NTA|258323590 | ||
| 996 | ‡2 ISNI|0000000030886528 | ||
| 996 | ‡2 SUDOC|066877156 | ||
| 996 | ‡2 BNE|XX6082140 | ||
| 996 | ‡2 LC|n 86008563 | ||
| 996 | ‡2 LC|no 97012183 | ||
| 996 | ‡2 BNE|XX6160286 | ||
| 996 | ‡2 PTBNP|175118 | ||
| 996 | ‡2 DNB|1057608769 | ||
| 996 | ‡2 LC|n 93033241 | ||
| 996 | ‡2 DNB|1042647607 | ||
| 996 | ‡2 BIBSYS|15027091 | ||
| 996 | ‡2 BNE|XX1116481 | ||
| 996 | ‡2 PLWABN|9811529256705606 | ||
| 996 | ‡2 BNF|12170066 | ||
| 996 | ‡2 ISNI|0000000060809603 | ||
| 996 | ‡2 LC|no2014050071 | ||
| 996 | ‡2 ISNI|0000000050531134 | ||
| 996 | ‡2 BNF|13747999 | ||
| 996 | ‡2 SELIBR|280440 | ||
| 996 | ‡2 DNB|1288204183 | ||
| 996 | ‡2 ISNI|0000000118525508 | ||
| 996 | ‡2 LC|nr 97028653 | ||
| 996 | ‡2 BNE|XX1752488 | ||
| 996 | ‡2 DE633|pe30049596 | ||
| 996 | ‡2 LC|n 95076395 | ||
| 996 | ‡2 LC|no2013104175 | ||
| 996 | ‡2 LC|n 2009056569 | ||
| 996 | ‡2 SUDOC|068646615 | ||
| 996 | ‡2 DNB|118792814 | ||
| 996 | ‡2 LC|no2007020859 | ||
| 996 | ‡2 BNF|18078072 | ||
| 996 | ‡2 BNCHL|10000000000000000291758 | ||
| 996 | ‡2 BNC|981058595003606706 | ||
| 996 | ‡2 NUKAT|n 98095608 | ||
| 996 | ‡2 ISNI|0000000059415834 | ||
| 996 | ‡2 LC|nr 97040606 | ||
| 996 | ‡2 LC|n 2010056601 | ||
| 996 | ‡2 DNB|124437893 | ||
| 996 | ‡2 RERO|A011262191 | ||
| 996 | ‡2 ISNI|0000000446210628 | ||
| 996 | ‡2 BNE|XX5828039 | ||
| 996 | ‡2 LC|n 90675862 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
